Goldman Sachs Resumed BioMed Realty (BMR) at Neutral

Goldman Sachs resumed coverage on BioMed Realty (NYSE: BMR) with a Neutral rating at a price target of $21. Analyst Matthew Rand said he sees better value elsewhere.

"BMR's earnings growth could be below the sector average in the coming years given ongoing challenges in the lab sector, additional tenant vacancies over the next few years, and higher G&A levels related to the Wexford acquisition," said Rand. "We continue to think that Digital Realty Trust (NYSE: DLR) offers better value as well as better growth within the more capital-intensive, slow-growth property sectors."

For an analyst ratings summary and ratings history on BioMed Realty click here. For more ratings news on BioMed Realty click here.

Shares of BioMed Realty closed at $20.50 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ford (F) earnings top estimates in Q1 amid strength in Pro unit; stock up
• First Bancorp. (FBNC) Misses Q1 EPS by 2c
• DAM Capital Starts Apollo Tyres (APTY:IN) at Buy